title: Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To assess the functional changes of retina in patients affected by polypoidal choroidal vasculopathy (PCV) after combined intravitreal bevacizumab and photodynamic therapy (PDT) by means of contrast sensitivity (CS) test and color vision test.
  
  
  METHODS
  Twelve eyes of 12 patients were included in the study. The CS and color vision were measured and compared before the combined treatment and 1, 3 and 6 months after the treatment.
  
  
  RESULTS
  The patients had an improvement in CS over pre-treatment values at the all of the five spatial frequencies. And the differences at 1.5 cycle per degree (cpd) at 1 and 3 months after treatment (p = 0.04 and 0.007 respectively) were statistically significant. The mean square root of total error score for color vision of the FM 100-hue test decreased after treatment and the change was significant at 3 and 6 months after treatment (p < 0.001 and 0.011 respectively).
  
  
  CONCLUSIONS
  Combined intravitreal bevacizumab and PDT can improve the CS at low spatial frequency and color vision in patients affected by PCV, although the significant increases of CS were no longer found at 6-month follow-up.
authors.affiliation: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlie Road, Guangzhou 510060, People's Republic of China.
authors.forename: Chengguo
authors.initials: C
authors.lastname: Zuo
authors.forename: Feng
authors.initials: F
authors.lastname: Wen
authors.forename: Jiaqing
authors.initials: J
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Shixian
authors.initials: S
authors.lastname: Long
authors.forename: Shizhou
authors.initials: S
authors.lastname: Huang
authors.forename: Meng
authors.initials: M
authors.lastname: Li
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D003119:Color Perception Tests; D055253:Color Vision / Q000187:drug effects; D015350:Contrast Sensitivity / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D011446:Prospective Studies; D020127:Recovery of Function / Q000187:drug effects; D013812:Therapeutics; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab